Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 15, 2026

Efficient Retroviral Transduction and Competitive Homing for Investigating GPCR-Mediated T-Cell Localization in Diverse Tissue Microenvironments
09:12

Efficient Retroviral Transduction and Competitive Homing for Investigating GPCR-Mediated T-Cell Localization in Diverse Tissue Microenvironments

Published on: March 28, 2025

Computer-guided dosing of multi-specific T-cell engagers.

Isaac Kendell1, Richard McShinsky2, Katarzyna Modzelewska2

  • 1Department of Biomedical Engineering, University of Utah, Salt Lake City, UT, USA. isaac.kendell@utah.edu.

Communications Biology
|July 13, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.

Blood advances·2026
Same author

BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma.

Cancer research·2026
Same author

Deep survival learning for prognosis prediction in non-metastatic castration-resistant prostate cancer.

Health informatics journal·2026
Same author

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Blood cancer journal·2026
Same author

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.

Blood cancer journal·2026
Same author

Development and Structural Characterization of UTE-156, a Covalent Inhibitor of the VCP/p97 AAA+ ATPase.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

This study introduces MATCH and COMPASS, a novel platform and computational framework for personalized T-cell immunotherapies. These tools predict optimal multi-specific treatments to enhance cancer cell killing while protecting T-cells.

Area of Science:

  • Immunology
  • Computational Biology
  • Oncology

Background:

  • Tumor heterogeneity challenges current T-cell immunotherapies.
  • Need for personalized treatment strategies in cancer therapy.

Purpose of the Study:

  • To develop a modular split-antibody T-cell engager platform (MATCH).
  • To create a computational framework (COMPASS) for predicting individualized multi-specific therapy compositions.
  • To optimize T-cell immunotherapy for patient-specific cancer treatment.

Main Methods:

  • Developed MATCH, a modular split-antibody T-cell engager platform.
  • Created COMPASS, a computational framework integrating T-cell counts, tumor burden, and antigen expression (CD19, CD20, CD38).
  • Validated COMPASS predictions using chronic lymphocytic leukemia patient PBMCs and a human lymphoma xenograft murine model.

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Related Experiment Videos

Last Updated: Jul 15, 2026

Efficient Retroviral Transduction and Competitive Homing for Investigating GPCR-Mediated T-Cell Localization in Diverse Tissue Microenvironments
09:12

Efficient Retroviral Transduction and Competitive Homing for Investigating GPCR-Mediated T-Cell Localization in Diverse Tissue Microenvironments

Published on: March 28, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Main Results:

  • COMPASS accurately predicted effective multi-specific formulations for patient-derived cells.
  • COMPASS-guided therapy significantly improved survival in a preclinical lymphoma model.
  • Demonstrated the ability to maximize tumor cell killing while preserving T-cell viability.

Conclusions:

  • MATCH and COMPASS offer a generalizable blueprint for precision T-cell immunotherapy.
  • This lab-in-the-loop approach represents a new paradigm in patient-specific cancer treatment.
  • Highlights the potential of computational frameworks in designing individualized immunotherapies.